Scientific Publications
and Presentations

Innovation and discovery drive our business. We are proud to share publications and presentations about our products and investigational pipeline candidates.

Please Select Year

Safety, tolerability and clinical implementation of ‘ready-to-use’ 68gallium-DOTA0-Tyr3-octreotide (68Ga-DOTATOC) (SomaKIT TOC) for injection in patients diagnosed with gastroenteropancreatic neuroendocrine tumours (GEP-NETs)

Manoharan P, Lamarca A, Navalkissoor S, Calero J, Chan PS, Julyan P, Sierra M, Caplin M, Valle J. ESMO Open (2020).

Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-DOTATATE: an analysis of the NETTER-1 study

Strosberg J, Kunz PL et al. on behalf of the NETTER-1 study group. Eur J Nucl Med Mol Imaging. (2020).

Radiation Safety Observations Associated with 177Lu Dotatate Patients

Nelson KL, Sheetz MA. Health Phys. (2019), pp 680-687.

Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer

Behr SC, Aggarwal R, VanBrocklin HF, Flavell RR, Gao K, Small EJ, Blecha J, Jivan S, Hope TA, Simko JP, Kurhanewicz J, Noworolski SM, Korn NJ, De Los Santos R, Cooperberg MR, Carroll PR, Nguyen HG, Greene KL, Langton-Webster B, Berkman CE, Seo Y. J Nucl Med. (2019), pp 910-916.

NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE

Hope TA, Abbott A, Colucci K, Bushnell DL, Gardner L, Graham WS, Lindsay S, Metz DC, Pryma DA, Stabin MG, Strosberg JR. J Nucl Med. (2019), pp 937-943.

Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy

Hennrich U, Kopka K. Pharmaceuticals. (2019).

Efficacy of 177Lu Peptide Receptor Radionuclide Therapy for the Treatment of Neuroendocrine Tumors: A Meta-analysis

Saravana-Bawan B, Bajwa A, Paterson J, McEwan AJB, McMullen TPW. Clin Nucl Med. (2019).

Therapy With 177Lu-DOTATATE: Clinical Implementation and Impact on Care of Patients With Neuroendocrine Tumors

Kendi AT, Halfdanarson TR, Packard A, Dundar A, Subramaniam RM. AJR Am J Roentgenol. (2019), pp 309-317.

Quality of life in patients with midgut NET following peptide receptor radionuclide therapy

Marinova M, Mücke M, Fischer F, Essler M, Cuhls H, Radbruch L, Ghaei S, Conrad R, Ahmadzadehfar H. Eur J Nucl Med Mol Imaging. (2019).

Caring for Patients Receiving 177Lu-DOTATATE, Lutathera®: A Treatment of Hope for Patients With Gastroenteropancreatic Neuroendocrine Tumors

Hromadik LK, Sturges L. J. Radiol. Nurs. (2019).

A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radioisotope Therapy for Patients With Neuroendocrine Tumors

Kasi PM, Maige CL, Shahjehan F, Rodgers JM, Aloszka DL, Ritter A, Andrus ML, Mcmillan JM, Mody K, Sharma A, Jain MK. Front. Oncol. (2019).

Peptide Receptor Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors

El Haddad G. Dig Dis Interv. (2018).

Impact of Liver Tumor Burden on Therapeutic Effect of 177Lu-DOTATATE Treatment in NETTER-1

J. Strosberg, A. Hendifar, J.C. Yao, M. Kulke, T. O’Dorisio, M. Caplin, R.P. Baum, P. Kunz, T. Hobday, E. Wolin, E.S. Mittra, K. Oberg, P. Ruszniewski, B. Polack, B. He, D. Barton, P. Santaro, E. Krenning.

EANM 2018: NETTER-1 Study Abstracts

Impact of Baseline Liver Tumor Burden on Treatment Outcomes with LUTATHERA® in the NETTER-1 Study (First author: Professor Jonathan Strosberg) - Renal Protection during LUTATHERA® Treatment Using Lysine and Arginine Solutions (First author: Professor Lisa Bodei) - Dosimetry of LUTATHERA® in Patients with Advanced Midgut Neuroendocrine Tumors: Results of the Phase III NETTER-1 Sub-Study (First author: Professor Lisa Bodei).

The recent European approval of lutetium (177Lu) oxodotreotide increases treatment options for gastroenteropancreatic neuroendocrine tumors

Caplin M. Int J Endocrine Onc (2018).